Breaking News - The Fly

Open Search

QLGN

Qualigen Therapeutics

$

()

Qualigen Therapeutics, Marizyme enter co-development agreement for DuraGraft

QLGN

4/16/2024 - 07:08am

Qualigen Therapeutics announces presentation on Pan-RAS Inhibitors

QLGN

4/10/2024 - 08:06am

Qualigen announces AACR poster featuring early clinical experience with QN-302

QLGN

4/9/2024 - 08:25am

Qualigen Therapeutics announces first patient dosed in Phase 1a trial of QN-302

QLGN

11/7/2023 - 08:43am

Qualigen Therapeutics announces poster highlighting Pan-RAS inhibitor platform

QLGN

10/23/2023 - 08:34am

Qualigen Therapeutics presents scientific data on QN-302 at AACR conference

QLGN

9/27/2023 - 08:35am

Qualigen Therapeutics partners with TD2 for Phase 1 development of QN-302

QLGN

8/17/2023 - 08:36am

Qualigen Therapeutics reports Q2 EPS (69c) vs ($1.12) last year

QLGN

8/15/2023 - 08:31am

Qualigen announces U.S. FDA IND clearance to initiate Phase 1 trial of QN-302

QLGN

8/1/2023 - 08:33am

Qualigen Therapeutics divests FastPack Diagnostics business

QLGN

7/24/2023 - 08:16am

One new option listing and eighteen option delistings on June 26th

TOON , QLGN , MDWD

…

6/26/2023 - 08:30am

Qualigen Therapeutics files to sell common stock, warrants, no amount given

QLGN

6/13/2023 - 17:17pm

Qualigen Therapeutics announces poster highlighting Pan-RAS inhibitor platform

QLGN

6/5/2023 - 08:47am

Qualigen Therapeutics reports Q1 EPS (78c) vs ($1.22) last year

QLGN

5/16/2023 - 08:05am